Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study |
| |
Authors: | Anne Floquet Adélaïde Doussau Véronique Brouste Laurent Cany Jean-Philippe Dutin Simone Mathoulin-Pélissier |
| |
Institution: | 1. Department of Medical Oncology, Institut Bergonié, 229 Cours de l’Argonne, 33076, Bordeaux, France 2. Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, 33000, Bordeaux, France 3. INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, CIC-EC7, 33000, Bordeaux, France 4. Clinical and Epidemiological Research Unit, Institut Bergonié, 229 Cours de l’Argonne, 33076, Bordeaux, France 5. Clinique Francheville, Périgueux, France 6. Centre Hospitalier de la C?te Basque, Bayonne, France
|
| |
Abstract: | Purpose This single-arm phase I dose-escalation study determines the optimal dose of the non-platinum treatment pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (CPM) every 4 weeks in early recurrent ovarian carcinoma. Methods Twenty-one women with ovarian carcinoma relapsing within 12 months of first-line surgery and platinum–taxane chemotherapy received escalating doses of PLD (35–45 mg/m2) and CPM (500–600 mg/m2) every 4 weeks for at least two cycles. Primary objective was assessment of maximum-tolerated dose (MTD) over the first two cycles. Secondary objectives were to assess safety over 2 cycles, efficacy evaluated every two cycles (response evaluation criteria in solid tumours criteria) and overall survival (OS). Results The PLD-CPM MTD was 40/600 mg/m2 with 2/3 patients treated at 45/500 mg/m2, showing DLTs with Grade 3/4 oesophagitis, thrombopenia/neutropenia, leucopoenia, and Grade 3 stomatitis/asthenia during the first cycle of treatment. Four severe toxicities were reported by three patients during the two first cycles, namely Grade 4 anaemia, and Grade 3 stomatitis. The most common treatment-related toxicities were anaemia (71.4 %), nausea (61.9 %), neutropenia (57.1 %), asthenia (52.4 %), leucopoenia (47.6 %), stomatitis (42.9 %), skin (28.6 %) and palmar–plantar–erythrodysesthesia (19 %). No treatment-related deaths were reported. The overall response rate (complete and partial) was 31 %, and median OS was 8.2 months 95 % CI (3.3–13.2)]. Conclusions The combination of PLD and CPM is feasible and may be considered particularly in cases where platinum-based treatment is not suitable. The recommended doses for a phase II trial are PLD 40 mg/m2 plus CPM 600 mg/m2 every 4 weeks. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|